Stay updated on Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Sign up to get notified when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.

Latest updates to the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check15 days agoNo Change Detected
- Check23 days agoChange DetectedThe webpage has been updated to reflect a new version of the trial documentation (v2.15.0) and includes the addition of collaborators and the principal investigator's name, while significant details about the trial's methodology and objectives have been removed.SummaryDifference54%
- Check30 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check37 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check66 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
- Check87 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1%
Stay in the know with updates to Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Cabozantinib and Erlotinib in Pancreatic Cancer Clinical Trial page.